Synairgen (SNG) RNS Announcements

Add to Alert list
Date Time Source Announcement
17 May 2017 07:00 AM
RNS
Preliminary Results
27 Apr 2017 07:00 AM
RNS
AZD9412 Update
27 Mar 2017 07:00 AM
RNS
Holding(s) in Company
13 Mar 2017 03:10 PM
RNS
Holding(s) in Company
10 Mar 2017 08:34 AM
RNS
Additional Positive Data in Lung Fibrosis
17 Jan 2017 02:46 PM
RNS
Holding(s) in Company
13 Oct 2016 10:44 AM
RNS
Holding(s) in Company
12 Oct 2016 07:00 AM
RNS
AZD9412 Clinical Trial Update
22 Sep 2016 07:00 AM
RNS
Interim results for six months ended 30 June 2016
08 Sep 2016 07:00 AM
RNS
Notice of Interim Results
14 Jun 2016 12:00 PM
RNS
Result of AGM
17 May 2016 07:00 AM
RNS
Posting of Annual Report and Notice of AGM
21 Apr 2016 02:14 PM
RNS
Holding(s) in Company
23 Mar 2016 07:00 AM
RNS
Exercise of Options
22 Mar 2016 07:00 AM
RNS
Preliminary results for the year ended 31 Dec 2015
22 Mar 2016 07:00 AM
RNS
Positive LOXL2 results
03 Mar 2016 07:00 AM
RNS
Notice of Preliminary Results
16 Nov 2015 04:11 PM
RNS
Adoption of FRS 101 - Reduced Disclosure Framework
13 Nov 2015 03:08 PM
RNS
Holding(s) in Company
13 Nov 2015 11:41 AM
RNS
Holding(s) in Company
13 Nov 2015 07:00 AM
RNS
Holding(s) in Company
12 Nov 2015 07:00 AM
RNS
Directors' Share Purchase
28 Oct 2015 07:00 AM
RNS
Grant of options
16 Sep 2015 07:00 AM
RNS
Interim Results
21 Aug 2015 07:00 AM
RNS
Notice of Interim Results
05 Aug 2015 07:00 AM
RNS
Synairgen announces research collaboration
22 Jul 2015 07:00 AM
RNS
AstraZeneca commences Phase II Trial
22 Jun 2015 01:41 PM
RNS
Result of AGM
02 Jun 2015 09:37 AM
RNS
Holding(s) in Company
15 May 2015 11:04 AM
RNS
Notice of AGM
22 Apr 2015 05:03 PM
RNS
Posting of Annual Report and Accounts
05 Mar 2015 12:55 PM
RNS
Richard Griffiths increases stake to 6.1 percent
03 Mar 2015 07:00 AM
RNS
Preliminary Results
12 Feb 2015 12:44 PM
RNS
Holding(s) in Company
11 Nov 2014 02:34 PM
RNS
Exercise of options
04 Nov 2014 07:00 AM
RNS
Grant of Options
08 Oct 2014 07:00 AM
RNS
Exercise of options
25 Sep 2014 07:00 AM
RNS
Interim results for the six months ended 30 June
17 Sep 2014 07:00 AM
RNS
Notice of Interim Results
22 Jul 2014 05:23 PM
RNS
Holding(s) in Company
22 Jul 2014 11:11 AM
RNS
Holding(s) in Company
22 Jul 2014 11:08 AM
RNS
Holding(s) in Company
21 Jul 2014 03:53 PM
RNS
Holding(s) in Company
16 Jul 2014 07:00 AM
RNS
Holding(s) in Company
15 Jul 2014 03:13 PM
RNS
Holding(s) in Company
04 Jul 2014 02:44 PM
RNS
Holding(s) in Company
04 Jul 2014 07:00 AM
RNS
Placing
25 Jun 2014 07:00 AM
RNS
Holding(s) in Company
12 Jun 2014 01:10 PM
RNS
Exercise of Options
12 Jun 2014 07:00 AM
RNS
Licence deal with AstraZeneca

Synairgen is a University spin-off and public limited company working in drug discovery and biotechnology. It was founded in 2003 by University of Southampton professors Stephen Holgate, Donna E. Davies and Ratko Djukanovic.

Synairgen is a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta candidate (SNG001) for severe viral lung infections.

Synairgen share price launched at 155p in 2004.

UK 100

Latest directors dealings